Company intelligence / Profile preview

Bio Preventive Medicine Corp.

Zhubei City, Hsinchu, Taiwantw.linkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

BPM has developed DNlite-IVD103, an ELISA-based non-invasive urinary test for monitoring the progression of diabetic kidney disease. The test can predict kidney function loss years in advance, unlike standard tests that only detect disease once present. It has been used in clinical trials including a phase IIIb global trial (MARLINA-T2D) sponsored by Boehringer Ingelheim.

Therapeutic areas: OncologyCardiovascularNephrology
Modalities: Diagnostic testsELISA-based tests
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

DNlite-IVD103

Commercial

Indications: Diabetic kidney disease, Kidney transplant monitoring

Partnerships

Boehringer IngelheimAndaman Medical (license holder for Vietnam and Indonesia)

Beyond the preview

Go deeper on Bio Preventive Medicine Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio Preventive Medicine Corp..

Explore the full profile